Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Accounts Payables: 2023-2024

Historic Accounts Payables for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $9.2 million.

  • Inhibrx Biosciences' Accounts Payables fell 45.25% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 45.25%. This contributed to the annual value of $9.2 million for FY2024, which is 15.60% down from last year.
  • According to the latest figures from FY2024, Inhibrx Biosciences' Accounts Payables is $9.2 million, which was down 15.60% from $11.0 million recorded in FY2023.
  • Inhibrx Biosciences' Accounts Payables' 5-year high stood at $11.0 million during FY2023, with a 5-year trough of $9.2 million in FY2024.
  • Over the past 2 years, Inhibrx Biosciences' median Accounts Payables value was $10.1 million (recorded in 2023), while the average stood at $10.1 million.
  • Data for Inhibrx Biosciences' Accounts Payables shows a maximum YoY decreased of 15.60% (in 2024) over the last 5 years.
  • Inhibrx Biosciences' Accounts Payables (Yearly) stood at $11.0 million in 2023, then dropped by 15.60% to $9.2 million in 2024.